News & Updates
Filter by Specialty:
Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
06 Jun 2022
byChristina Lau
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.
Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
06 Jun 2022
NAFLD tied to CVD risk even in lean patients
06 Jun 2022
byElvira Manzano
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
